The lacrimal gland secretes water, electrolytes, and protein into the tear film. Decreased secretion from the lacrimal gland can lead to dry eye syndromes with deleterious effects on vision. Protein kinase C (PKC)-␣ plays a major role in cholinergic-and ␣ 1 -adrenergic-induced protein secretion from the lacrimal gland. This study was undertaken to determine whether activation of PKC␣ alone would induce lacrimal gland protein secretion by examining the effects of overexpression of constitutively active PKC␣. METHODS. Rat lacrimal gland acini were transduced with an adenovirus containing a gene for constitutively active PKC␣. Protein secretion was measured in response to cholinergic and ␣ 1 -adrenergic agonist stimulation.
T he primary function of tears is to protect the cornea and conjunctiva, which together compose the ocular surface. Tears are secreted in response to environmental stresses and protect the ocular surface by providing nourishment to the avascular cornea. 1 The lacrimal gland is a tubuloacinar exocrine gland that functions to synthesize, store, and secrete proteins and electrolytes into the tear film, leading to the formation of the aqueous layer of tears. 1 If this secretion is altered in either amount or composition, a spectrum of diseases called dry eye syndromes results. 1 In these types of diseases, symptoms of itchiness, irritation, and feelings of dryness occur. In severe dry eye, vision-threatening conditions such as corneal ulcers and loss of corneal transparency can occur. 1 Dry eye syndromes are a leading cause of ocular difficulties, with more than 3.2 million women in the United States alone diagnosed with these disorders. 2 The lacrimal gland is composed of three main cell types: the acinar cells which are the main secretory cells; the ductal epithelial cells which line the ducts and modify the fluid by secreting water and electrolytes; and myoepithelial cells, which surround the acini with long processes. 1 The lacrimal gland is highly innervated with parasympathetic and sympathetic nerves, and the neurotransmitters released from these nerves are potent stimuli of protein secretion. [3] [4] [5] [6] Cholinergic agonists released from parasympathetic nerves bind to M 3 muscarinic receptors. 7 These receptors are G-protein-coupled receptors coupled to phospholipase C␤ (PLC␤). 7, 8 Activated PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate inositol 1,4,5-trisphosphate (1,4,5-IP 3 ) and diacylglycerol (DAG).
9,10 1,4,5-IP 3 causes the release of Ca 2ϩ from intracellular Ca 2ϩ [Ca 2ϩ ] i stores that can stimulate secretion, either on its own or through enzymes such as Ca 2ϩ /calmodulin-dependent protein kinases and protein kinase C (PKC). [11] [12] [13] [14] DAG is necessary for the activation of PKC. ␣ 1 -Adrenergic agonists released from sympathetic nerves also stimulate lacrimal gland protein secretion, though the signaling pathway is not as well characterized as the pathway used by cholinergic agonists. 15, 16 The specific types of ␣ 1 -adrenergic receptors present in the lacrimal gland are unknown, as is the primary G protein activated used by these agonists. The phospholipase activated by the G-proteins is also unknown. It is known that ␣ 1 -adrenergic agonists cause release of [Ca 2ϩ ] i , though to a much lesser extent than cholinergic agonists. 16 ␣ 1 -Adrenergic agonists are also known to activate PKC. 15, 16 Our laboratory has shown that PKC plays a major role in both cholinergic-and ␣ 1 -adrenergic-stimulated lacrimal gland protein secretion. 15 However, as PKC is a family of at least 10 different isozymes, its role is somewhat complicated. The family of PKCs are divided into three groups. 17, 18 The classical PKC isoforms, PKC-␣, -␤I, -␤II, and -␥, are calcium and phospholipid dependent. The novel PKC isoforms, PKC-␦, -⑀, -, and -, are calcium independent and phospholipid dependent. The final group is the atypical PKC isoforms consisting of PKCand -. These PKC isoforms are calcium and phospholipid independent. Translocation of PKC isoforms to a membrane structure is an indication of enzyme activation. Anchoring proteins called receptors for activated C-kinase (RACKS) have been shown to provide isoform specificity by binding the activated isoforms and recruiting them to the appropriate substrates. 19 The lacrimal gland contains PKC-␣, -␦, -⑀, and -. 20 Using selective isoform inhibitors for PKC␣, -␦, and -⑀, we found that these three isoforms play roles in cholinergic-agonist-stimulated secretion, with PKC␣ playing the major role. 15 In contrast, activation of PKC␣ and ␦ inhibits ␣ 1 -adrenergic-agoniststimulated secretion, whereas activation of PKC⑀ stimulates secretion. 15 In addition to having a direct role in protein secretion, PKC has been shown to alter cellular calcium handling in the lacri-mal gland. Activation of PKC with phorbol esters decreases the production of 1,4,5-IP 3 and the Ca 2ϩ response induced by cholinergic agonists. [21] [22] [23] [24] Using specific PKC isoform inhibitors, we found that the Ca 2ϩ -independent PKC isoform PKC␦, and to a lesser extent PKC⑀, reverses the effect of phorbol esters on the Ca 2ϩ response. 22 In contrast the Ca 2ϩ -dependent PKC isoform PKC␣ had no effect. 22 We hypothesized that activation of PKC␦, and to a lesser extent PKC⑀ but not PKC␣, blocks the Ca 2ϩ entry process stimulated by cholinergic agonists. 22 With the development of adenoviral vectors and more efficient transfection procedures in combination with molecular biology techniques, the role of a particular signaling molecule can be more thoroughly studied. Constitutively active and dominant negative mutants of many signaling molecules have been generated and overexpressed in target cells. [25] [26] [27] [28] [29] The effects of these proteins were then measured on various cellular functions. In particular, constitutively active or dominant negative PKC isoforms have been used to provide additional information regarding its downstream effects. 30, 31 As PKC inhibitors can be nonspecific or difficult to use, these techniques can provide a valuable tool for studying the role of specific isoforms. As the lacrimal gland contains multiple isoforms of PKC, we wanted to examine further the role of a specific isoform, namely PKC␣, in Ca 2ϩ handling and protein secretion. Thus, we overexpressed a constitutively active form of PKC␣, by using an adenoviral vector, and investigated its effects on protein secretion and [Ca 2ϩ ] i handling. 
MATERIALS AND METHODS

Generation of Myristoylated PKC␣ Construct Adenoviruses
A myristoylated PKC␣ construct was synthesized as previously described. 31 In brief, an ␣-Flag epitope (DYKDDDDK) was added to the carboxyl terminus of the PKC␣ cDNA, and an Src myristoylation site (MYPYDVPDYA) was added to the amino terminus. The myristoylation moiety targets PKC␣ to cell membranes, resulting in kinase activity in vitro that has been shown to be higher than in wild-type PKC␣. 31 Recombinant-deficient adenoviruses containing myr-PKC␣ (AdV-myr-PKC␣) and green fluorescent protein (AdV-GFP) were generated and purified at the Harvard Gene Therapy Center (Boston, MA).
Preparation of Rat Lacrimal Gland Acini and Infection with Adenovirus
All experiments conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Schepens Eye Research Institute Animal Care and Use Committee. Both exorbital lacrimal glands were removed from male Sprague-Dawley rats that had been anesthetized with CO 2 and then decapitated. Lacrimal glands were trimmed of fatty and connective tissue and fragmented into small pieces. The pieces were washed at 37°C in Krebs-Ringer bicarbonate buffer (119 mM NaCl, 4.8 mM KCl, 1 mM CaCl 2 , 1.2 mM KH 2 PO 4 , and 25 mM NaHCO 3 ) supplemented with 10 mM HEPES, 5.5 mM glucose, and 0.5% BSA (pH 7.4; KRB-BSA). Lacrimal gland acini were prepared by incubating tissue pieces with collagenase CLS III, (100 U/mL) in KRB-BSA for 30 minutes at 37°C under a stream of 95% O 2 -5% CO 2 . The preparation was then filtered through nylon mesh (150 m) and the acini collected with 3-minute centrifugation at 50g. The dispersed acini were allowed to recover for 45 minutes in fresh KRB-BSA. Lacrimal gland acini were pelleted; resuspended in RPMI 1640 medium supplemented with 0.5% BSA, 2 mM L-glutamine and 100 g/mL penicillin-streptomycin; and incubated (150 g protein/well) at 37°C in 95% O 2 -5% CO 2 . The viruses AdV-GFP and AdV-myrPKC␣ were added at the concentrations indicated to the acini for 18 hours. It is important to note that acini are clumps in the figure legends composed of various numbers of cells. Thus, it is impossible to determine the exact number of cells in a particular preparation. Therefore, the multiplicities of infection (MOIs) used in this study were described as plaque-forming units per micrograms of protein.
Measurement of Protein Secretion
Lacrimal gland acini were incubated in the presence or absence of adenoviruses for 18 hours and removed from cell culture plates. Acini were washed with KRB-BSA, allowed to recover for 45 minutes in fresh KRB-BSA, and incubated for 20 minutes with either the cholinergic agonist carbachol or the ␣ 1 -adrenergic agonist phenylephrine in KRB-BSA. To terminate incubation, acini were centrifuged at 50g and placed on ice. The supernatant was removed and the acini (pellet fraction) were disrupted by sonication in 50 mM Tris-HCl (pH 8.0). Peroxidase secretion, an index of protein secretion in lacrimal gland was measured. Peroxidase activity was measured in both the supernatant and the pellet fraction using a peroxidase detection agent (Amplex Red; Molecular Probes). Peroxidase oxidizes the agent in the presence of hydrogen peroxide to produce resorufin, a highly fluorescent molecule. For the measurement of peroxidase, supernatant and acini homogenate were spotted in duplicate onto 96-well microplates. Assay buffer (50 mM Tris-HCl, pH 7.5) containing 0.2 M peroxidase detector and 0.2 M hydrogen peroxide was added to each well. The fluorescence was determined in a fluorescence microplate reader (model FL600; Bio-Tek, Winooski, VT) with 530-nm excitation wavelength and 590-nm emission wavelength. The amount of secreted peroxidase was expressed as a percentage of the total: (peroxidase in medium/peroxidase in medium ϩ peroxidase in tissue) ϫ 100.
Western Blot Analysis
Lacrimal gland acini were incubated in the presence or absence of adenoviruses for 18 hours and removed from cell culture plates. The acini were homogenized in ice-cold RIPA buffer containing proteinase inhibitors (10 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% SDS, 1 mM EDTA, 10 mg/mL phenylmethylsulfonyl fluoride, 5 U/mL aprotinin, and 100 nM sodium orthovanadate) and proteins were separated by SDS-PAGE (10% acrylamide gel). The proteins were then transferred to nitrocellulose membranes. For the anti-PKC␣ antibody, nonspecific sites were blocked by incubating membranes overnight at 4°C in 5% dried milk in buffer containing 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 0.05% Tween-20 (TBST), followed by incubation for 1 hour at room temperature with the primary antibody to PKC␣ (1:2000) . For anti-phosphorylated PKC␣ antibody, the membranes were blocked for 1 hour at room temperature in 5% dried milk in TBST followed by overnight incubation with primary antibody (1:1000) in 5% BSA in TBST. After primary antibody incubation, all membranes were washed in TBST and incubated with the secondary antibody conjugated to horseradish peroxidase (1:2000) . Immunoreactive bands were visualized by the enhanced chemiluminescence method. The films were scanned and analyzed with National Institutes of Health Image software (available by ftp at zippy.nimh.nih.gov/ or at http://rsb.info.nih.gov/nih-image; developed by Wayne Rasband, National Institutes of Health, Bethesda, MD).
Flow Cytometry and Confocal Immunofluorescence Microscopy
The percentage of lacrimal gland acinar cells expressing GFP was determined using the FITC channel. In some experiments, lacrimal gland acinar cells were fixed with PBS containing 0.5% BSA and 4% paraformaldehyde for 20 minutes and incubated with the primary antibodies (anti-flagM2 or anti-PKC␣; 1:50) in PBS containing 0.5% BSA and 0.1% saponin for 20 minutes. Cells were rinsed three times with PBS and 0.5% BSA and incubated with FITC-conjugated secondary antibodies (1:50) for 20 minutes. Cells were rinsed three times and analyzed by flow cytometry with a cell counter (Epics XL Analyzer; Beckman Coulter Inc., Hialeah, FL).
For confocal microscopy, lacrimal gland acini were incubated with and without the cholinergic agonist carbachol (10 Ϫ4 M) for 5 minutes after transduction with 3 ϫ 10 7 pfu/150 g protein. The cells were cytospun onto gelatin-coated slides by a cytospin centrifuge (Shandon, Pittsburgh, PA) running at 1000 rpm for 4 minutes. The slides were air dried and fixed in 4% formaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) with 15 mM CaCl 2 for 20 minutes and preserved in 30% sucrose in sodium phosphate buffer with 15 mM CaCl 2 for 20 minutes. The slides were air dried and stored at Ϫ20°C. Before addition of antibodies, acini were permeabilized with 1% Triton X-100 diluted in PBS (containing 145 mM NaCl, 7.3 mM Na 2 HPO 4 , and 2.7 mM NaH 2 PO 4 ) for 10 minutes at room temperature. The antibody against PKC␣ was used at a 1:1000 dilution for 1 hour at room temperature. The secondary antibody, conjugated to either FITC or rhodamine was used at 1:200 for 1 hour at room temperature. The slides were viewed with a confocal scanning microscope (TCS4D; Leica Microsystems, Bannockburn, IL) equipped with a krypton-argon laser.
Measurement of [Ca 2؉ ] i
After overnight incubation with 3 ϫ 10 7 pfu/mL of either AdV-GFP or AdV-myrPKC␣, acini were allowed to recover for 30 minutes at 37°C in KRB-BSA buffer. Acini were then incubated in KRB-BSA buffer containing 0.5% BSA, 0.5 M fura-2 tetraacetoxymethyl ester, 10% pluronic F127, and 250 M sulfinpyrazone for 60 minutes at 22°C. The cells were then washed with KRB-BSA buffer containing 250 M sulfinpyrazone, and fluorescence was measured at 22°C. Fluorescence was measured at excitation wavelengths of 340 and 380 nm and an emission wavelength of 505 nm using a luminescence spectrofluorometer (model LS-5B; Perkin Elmer, Wellesley, MA). To calculate [Ca 2ϩ ] i , 5.6 mM EGTA, 7.5 mM Tris-HCl (pH 7.5), and 1% Triton X-100 were added at the end of the reaction to obtain the minimum fluorescence level. Maximum fluorescence was determined by the addition of 14.5 mM CaCl 2 . The dissociation constant of 135 nM for fura-2 at 22°C was used to calculate [Ca 2ϩ ] i by the ratio method.
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Data Presentation and Statistical Analysis
Data are expressed as the mean Ϯ SEM. When appropriate, data were statistically analyzed with Student's t-test for unpaired values. P Ͻ 0.05 was considered to be significant.
RESULTS
Transduction of Rat Lacrimal Gland Acini by Adenovirus AdV-GFP
To determine the conditions necessary for optimal adenoviral transduction, lacrimal gland acini were incubated with various concentrations of AdV-GFP for various times. The GFP expressed within the acinar cells was viewed by fluorescence microscopy, using the FITC wavelength. Fluorescence microscopy showed that lacrimal acini were maximally transduced after 18 hours by AdV-GFP at 3 ϫ 10 7 pfu/150 g protein and that GFP was present in almost every cell throughout the acinus (Fig. 1A) . Because it was impossible to determine the number of cells in an acini preparation, MOIs are expressed as plaque-forming units (pfu) per 150 micrograms of protein.
When analyzed by flow cytometry, 88% Ϯ 5% of lacrimal acinar cells expressed GFP when transduced by AdV-GFP under these conditions (Fig. 1B) .
These results show that freshly isolated lacrimal gland acini can be transduced using an adenovirus containing the gene for GFP, resulting in expression of the GFP protein.
Overexpression of PKC␣ in AdV-myrPKC␣-Transduced Lacrimal Gland Acini
The myrPKC␣ construct contains an ␣-FLAG epitope on the carboxyl terminus of the PKC␣ gene. Thus, using the same conditions of transfection for AdV-GFP, we used confocal microscopy to view ␣-FLAG in transduced acini and flow cytometric analysis to determine the number of cells expressing ␣-FLAG and thus PKC␣. After incubation for 18 hours with AdV-myrPKC␣ (3 ϫ 10 7 pfu/150 g cell protein), acini were cytospun onto slides and incubated with an anti-␣-FLAG antibody. Confocal microscopy showed that the ␣-FLAG epitope was located in the plasma membranes and outlined the individual cells within the acinus (Fig. 2B) . In addition, flow cytometric analysis determined that 84.0% Ϯ 0.2% of acinar cells expressed the ␣-Flag epitope (Fig. 2B) . This epitope was absent in noninfected acini ( Fig. 2A) .
To confirm these results, rat lacrimal gland acini were transduced with AdV-myrPKC␣ for 18 hours. Expression of myr-PKC␣ was then determined in cell homogenates by Western blot techniques with an anti-PKC␣ antibody. Figure 3A shows the expression of PKC␣ in nontransduced acini and in acini transduced by increasing concentrations of AdV-myrPKC␣ (3 ϫ 10 5 to 10 8 pfu/150 g cell protein). When the blots were analyzed by densitometry (Fig. 3B) , PKC␣ expression was 176 times higher in cells transduced with 3 ϫ 10 7 pfu/150 g cell protein than in nontransduced acini (n ϭ 3). Overexpression of PKC␣ was dependent on the MOI, with the highest expression corresponding to the highest concentration of AdV-myr-PKC␣.
These results show that freshly isolated lacrimal gland acini can be efficiently transduced using an adenovirus containing the gene for constitutively active PKC␣, resulting in expression of the PKC␣ protein.
Localization of myrPKC␣
The myristoylation moiety on the amino terminus of the PKC␣ construct should target PKC␣ to cell membranes, thereby activating it. Confocal microscopy showed that the ␣-FLAG epitope appeared to be located in the plasma membrane. To verify the location of the myrPKC␣ expressed by transduced lacrimal gland acini, acini were cytospun onto slides and incubated with an anti-PKC␣ antibody. The localization of PKC␣ was then determined by confocal microscopy. In unstimulated, nontransduced acini, PKC␣ had diffuse, cytosolic staining (Fig.  4A) . As expected, in nontransduced acini, PKC␣ localization changed on stimulation with the cholinergic agonist carbachol (10 Ϫ4 M) and appeared to localize to the basolateral membranes (Fig. 4B) . In cells transduced with AdV-myrPKC␣, but not stimulated, and viewed by confocal microscopy, PKC␣ was located in the plasma membranes (Fig. 4C) . This location is consistent with the localization seen using the antibody against ␣-FLAG epitope.
These results indicate that endogenous PKC␣, in nontransduced acini, translocates to the plasma membrane on stimulation with cholinergic agonists. However, constitutively active myrPKC␣ in transduced acini is already located in the plasma membrane of freshly isolated lacrimal gland acini.
PKC Activity in AdV-myrPKC␣-Transduced Lacrimal Gland Acini
It has been reported that myristoylated PKC␣ has increased kinase activity in vitro relative to the wild-type enzyme. 19 To ensure that the PKC␣ expressed in myrPKC␣-transduced lacrimal gland acini was constitutively active, PKC activity was compared in nontransduced and transduced acini. Acini were transduced with 3 ϫ 10 7 pfu/150 g protein overnight before stimulation with the phorbol ester, PMA, a known activator of PKC, at 10 Ϫ6 M for 10 minutes. The reaction was terminated by centrifugation, acini were homogenized in RIPA buffer, and proteins were separated by SDS-PAGE. Because PKC activation is regulated by phosphorylation at three sites, Thr 500 in the activation loop, Thr 638 in the autophosphorylation site, and Ser 660 in the hydrophobic site of the carboxyl terminus, 33 we used an antibody against PKC␣ phosphorylated at Thr 638 in Western blot analysis. As shown in Figure 5A , activated PKC␣ was not detected in nontransduced acini until stimulated with PMA. In contrast, there was a substantial amount of activated PKC␣ in transduced acini. There was no further increase in the amount of activated PKC␣ in transduced acini after stimulation 
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with PMA. The same samples were also analyzed using an antibody to total PKC␣ (Fig. 5B ) to ensure that transduction had occurred. These results indicate that PKC␣ in transduced lacrimal gland acini is constitutively active.
Effect of Overexpression of myrPKC␣ on Stimulated Protein Secretion
To determine whether overexpression of activated PKC␣ has an effect on protein secretion stimulated by neurotransmitters, lacrimal gland acini were transduced with either AdV-GFP or AdV-myrPKC␣ (3 ϫ 10 7 pfu/150 g protein) before stimulation with the cholinergic agonist carbachol (10 Ϫ3 M) or the ␣ 1 -adrenergic agonist phenylephrine (10 Ϫ3 M). Peroxidase, our index of protein secretion, was measured. As shown in Figure  6 , basal secretion in nontransduced acini was 0.28% Ϯ 0.08% of total peroxidase (n ϭ 6) and was significantly increased by stimulation with carbachol (0.75% Ϯ 0.22% of total peroxidase) and phenylephrine (1.20% Ϯ 0.28% of total peroxidase). Basal secretion in acini transduced with AdV-GFP decreased slightly, though not significantly, from basal secretion in nontransduced acini (0.17% Ϯ 0.01% of total peroxidase, n ϭ 6). Carbachol and phenylephrine again significantly increased peroxidase secretion over their basal in acini transduced with AdV-GFP (0.36% Ϯ 0.02% and to 1.22% Ϯ 0.04% of total peroxidase, respectively, Fig. 6 ). Basal secretion was significantly increased in acini transduced with AdV-myrPKC␣ to 0.89% Ϯ 0.04% of total peroxidase compared with basal secretion in nontransduced acini (n ϭ 6). In contrast to nontransduced and AdV-GFP-transduced acini, carbachol stimulation did not further increase peroxidase secretion in AdV-myrPKC␣ transduced acini (0.69% Ϯ 0.02% of total peroxidase, Fig. 6 ) above its basal. There was no significant difference in carbachol-stimulated peroxidase secretion between nontransduced acini and acini transduced with either AdV-GFP or AdV-myr-PKC␣. Phenylephrine, however, significantly increased peroxidase secretion to 1.94% Ϯ 0.11% of total peroxidase in acini transduced with AdV-myrPKC␣ over its basal secretion. Phenylephrine-induced peroxidase secretion was not significantly different between nontransduced acini and acini transduced with either AdV-myrPKC␣ or AdV-GFP. These results imply that PKC␣ plays a role in basal and carbachol-induced, but not phenylephrine-induced, peroxidase secretion from freshly isolated lacrimal gland acini.
Effect of Overexpression of myrPKC␣ on Basal Protein Secretion
As indicated in Figure 6 , overexpession of myr-PKC␣ caused a statistically significant increase in basal secretion (i.e., secretion in the absence of exogenous stimuli). To investigate this response further, acini were transduced with increasing concentrations of AdV-myrPKC␣ overnight, and basal peroxidase secretion was measured. Basal secretion rose with the increasing concentrations of AdV-myrPKC␣ used for transfection (Fig.  7) . Statistically significant increases in peroxidase secretion over nontransduced acini were obtained with concentrations of 10 6 , 3 ϫ 10 6 , 3 ϫ 10 7 , and 10 8 pfu/g protein. These results indicate that increasing the expression PKC␣ increases basal peroxidase secretion and are consistent with the presence of active PKC␣.
Effect of Overexpression of myrPKC␣ on [Ca 2؉ ] i Concentration
To determine whether the increase in basal peroxidase secretion was a result of altered [Ca 2ϩ ] i handling, the [Ca 2ϩ ] i was measured with the calcium indicator fura-2 in acini transduced with 3 ϫ 10 7 pfu/g protein of either AdV-GFP or AdV-myr-PKC␣. Basal [Ca 2ϩ ] i in nontransduced acini was 20.9 Ϯ 2.3 nM (n ϭ 4). This level was not altered in acini tranduced with AdV-GFP (19.0 Ϯ 0.4 nM, n ϭ 4) or AdV-myrPKC␣ (16.8 Ϯ 1.9 nM, n ϭ 4). To ensure that changes in [Ca 2ϩ ] i could be detected in these cells, the ␣ 1 -adrenergic agonist phenylephrine, which is known to increase [Ca 2ϩ ] i in lacrimal gland acini, was added to nontransduced and transduced acini. 16 Phenylephrine (10 Ϫ4 M) elicited an increase in [Ca 2ϩ ] i by 12.0 Ϯ 7.1, 18.6 Ϯ 7.5, and 14.9 Ϯ 4.3 nM over basal levels in nontransduced acini and acini transduced with either 3 ϫ 10 7 pfu/g protein AdV-GFP or AdV-myrPKC␣, respectively.
Thus, these results indicate that altered Ca 2ϩ handling does not play a role in increased basal protein secretion.
DISCUSSION
When the lacrimal gland ceases to secrete proteins and electrolytes in the appropriate quantity, dry eye syndromes result. The causes of lacrimal gland dysfunction vary and can range from normal aging to destruction of the gland. Indeed, the autoimmune disease Sjögren's syndrome is characterized by lymphocytic infiltration of the lacrimal gland and a subsequent decrease in protein secretion. We have shown in a mouse model of Sjögren's syndrome that the innervation in lacrimal glands is unchanged with the onset and progression of the disease. 34 However, the release of neurotransmitters by nerves surrounding lacrimal gland acini was inhibited, resulting in a denervation-like supersensitivity. 35 By identifying the location of the defect in Sjögren's syndrome or other dry eye syndromes, it should then be possible to design therapies that bypass the obstruction and restore lacrimal gland secretion. Thus, expression of a constitutively active form of PKC␣ could circumvent the need for released neurotransmitters and activation of their receptors.
In this study, we show that a constitutively active form of PKC␣ can be overexpressed through an adenoviral vector in lacrimal gland acini. This transduction is very efficient, as PKC␣ can be overexpressed in more than 85% of lacrimal gland acini. This results in a 176-fold increase in expression of constitutively active PKC␣ over nontransduced cells. This expression increases basal secretion while not affecting [Ca 2ϩ ] i . In general, PKC isoforms have cell-and tissue-specific localizations. The cellular location of PKC has been shown to be critically important to the regulation and function of the enzyme in a variety of cell types. 19, 36, 37 The lacrimal gland is no exception. Of the four PKC isoforms present in the lacrimal gland, each has a specific cellular location. 20 Of interest to this study, PKC␣ was located in lacrimal gland sections on the basolateral and apical membranes of the acini, although Western blot analysis indicated that a substantial amount of PKC␣ was located in the cytosolic fraction of unstimulated acini. PKC␣ was translocated to the membrane fraction on stimulation, but the location was not determined. 20 In this study, confocal microscopy confirmed that PKC␣ was located in the cytosol of acini and was translocated to the basolateral membranes on stimulation with the cholinergic agonist carbachol. This location is similar to that seen with the overexpressed constitutively active PKC␣. Thus, constitutively active PKC␣ appears to be located in the basolateral membranes of acinar cells, the proper location for exerting its functional effects.
We have shown that PKC␣ plays a major role, both positive and negative, in cholinergic and ␣ 1 -adrenergic agonist-induced protein secretion. 15 Thus, it is surprising that the effect of overexpression of PKC␣ was to increase basal secretion (i.e., absence of stimuli). The increase was dependent on the con- Constitutively Active PKC␣ in Lacrimal Gland 3979 centration of adenovirus used and therefore the amount of PKC␣ expressed, implying that PKC␣ plays a major role in producing basal protein secretion. Overexpression of wildtype PKC⑀ has also been shown to increase basal secretion of prolactin from rat pituitary cells. 38 Akita et al. 38 determined that the amount of PKC⑀ associated with membrane fractions was higher in cells overexpressing PKC⑀ than in control cells, resulting in increased enzyme activity and an increase in basal secretion. They suggest that the amount of PKC⑀ in these cells is rate limiting in the basal secretory pathway, and thus more PKC⑀ leads to more secretion. In the lacrimal gland, the amount of PKC␣ could also be rate limiting in basal secretion, with overexpression of PKC␣ resulting in increased basal secretion. This could be advantageous when designing a treatment to stimulate tear secretion in patients with dry eye syndromes, as the number of compounds needed to be introduced for effective treatment would be low.
Although cholinergic and ␣ 1 -adrenergic agonists activate the same PKC isoforms, namely PKC␣, -␦, and -⑀, the effects of activation are quite different. Cholinergic agonists translocate these isoforms from cytosolic to membrane fractions; ␣ 1 -adrenergic agonists do not. 16 Activation of PKC␣, -␦, and -⑀, as measured using pseudosubstrate inhibitor peptides, stimulate cholinergic agonist-induced protein secretion, whereas activation of PKC␣ and -␦ inhibits ␣ 1 -adrenergic agonist-stimulated protein secretion, and PKC⑀ stimulates it. PKC isoforms are known to interact with several binding proteins that are responsible for targeting PKC to the appropriate location, bringing the enzyme in close proximity to its substrates and integrating the signal with other signaling pathways. 36 We hypothesized that different agonists are distinctly coupled to the PKC isoforms to account for the differing effects. This is further supported by the present study, in which stimulation of protein secretion by carbachol in acini overexpressing PKC␣ was not increased, whereas phenylephrine stimulated secretion in these cells.
The differences seen between the effects of cholinergic and ␣ 1 -adrenergic agonists are striking. Cholinergic agonists do not stimulate secretion over basal levels in acini overexpressing PKC␣, whereas secretion is stimulated by ␣ 1 -adrenergic agonists. This suggests that cholinergic agonists activate PKC␣ to stimulate secretion and, because PKC␣ has already been activated, they cannot further activate PKC␣. Thus, cholinergic agonists cannot increase secretion over the already elevated levels. It is possible that cholinergic agonists use a different signaling pathway than that used to maintain basal secretion. In this case, instead of the amount of PKC␣ being rate limiting, the amount of another protein downstream of PKC␣ would be rate limiting. ␣ 1 -Adrenergic agonists can increase secretion over basal levels, suggesting that they do not use the same signaling pathway as activated by cholinergic agonists or the pathway that maintains basal secretion. ␣ 1 -Adrenergic agonist use PKC⑀ to stimulate protein secretion and thus can activate this PKC isoform in cells in which PKC␣ is constitutively active.
We have shown previously, with isoform-specific inhibitors, that PKC␣ is not involved in the Ca 2ϩ response induced by cholinergic agonists, but the effects on the Ca 2ϩ response stimulated by ␣ 1 -adrenergic agonists was not determined. 22 It is interesting that activation of PKC␣ is sufficient to increase basal protein secretion in the absence of an increase in [Ca 2ϩ ] i , as we have shown that cholinergic and ␣ 1 -adrenergic agonists increase [Ca 2ϩ ] i and this increase is necessary for secretion to occur. 11, 16 It is possible that there was a localized, but undetected, increase of [Ca 2ϩ ] i in a microdomain that was sufficient to increase protein secretion. The results in this study confirm the hypothesis that additional PKC isoforms, other than PKC␣, are involved in Ca 2ϩ handling in the lacrimal gland.
It is not clear whether the effects on basal peroxidase secretion in this study are a result of the overexpression of PKC␣ or of the fact that PKC␣ is constitutively active. Experiments with an adenovirus containing a wild-type PKC␣ did not increase basal protein secretion. However, the total amount of PKC␣ expressed in acini transduced with wild-type PKC␣ was significantly less than in acini transduced with myrPKC␣. Indeed, we were unable to achieve a level of expression of wild-type PKC␣ that was comparable to the level achieved with myrPKC␣. Transduction of acinar cells with 1 ϫ 10 8 pfu/150 g protein resulted in only a threefold increase in PKC␣ expression, as measured by Western blot techniques (data not shown). It is unlikely, however, that the effects are a result only of overexpression of PKC␣, as we showed that myrPKC␣ was found in the plasma membrane, the same location as endogenous PKC␣ when translocated by cholinergic agonists. Wild-type PKC␣ would not be in the appropriate location under basal conditions to exert any effects.
It has been suggested that certain proteins in the adenoviral coat uncouple the secretory pathway stimulated by cholinergic agonists in lacrimal gland acini. 39 This study shows that there is a reduced amount of secretory vesicles containing rab3D in cells treated with the penton protein, resulting in an increased basal protein secretion and decreased stimulated protein secretion. In contrast, Chen et al. 40 did not detect changes in location of Rab3D and either basal or stimulated amylase secretion in pancreatic acini transduced with either control adenovirus or an adenovirus encoding Rab3D. In the present study, we also saw an increase in basal secretion. However, this effect occurred only when we used AdV-myrPKC␣ and not with AdV-GFP, indicating that the effect on secretion was not due to the adenovirus itself. The differences might be explained by the fact that the lacrimal gland acini used in the study by Wang et al. 41 were reconstituted by culturing acini from rabbit lacrimal glands in medium for several days, allowing them to re-form into a structure resembling an acinus. In addition, Wang et al. were measuring total protein secretion compared with regulated protein secretion, as measured in the present study. Finally, the duration of exposure to the adenovirus and the MOI used have been shown to alter the effects of the adenovirus itself. We are unable to determine cell number to calculate MOI in our preparations, making comparisons between these studies difficult.
We observed that basal and cholinergic agonist-stimulated peroxidase secretion is decreased in acini transduced with AdV-GFP. Although this decrease is not statistically significant, it is notable. The decrease could be due to the adenoviral vector itself, although this effect was not seen when acini were stimulated with ␣ 1 -adrenergic agonists. It could also be due to the expression of the GFP protein. This also seems unlikely as again, the effect did not occur when acini were stimulated with ␣ 1 -adrenergic agonists.
In conclusion, overexpression of a constitutively active form of PKC␣ increases basal protein secretion, but does not alter Ca 2ϩ handling, in the lacrimal gland. Thus, in the lacrimal gland, secretion can be stimulated by circumventing the release of neurotransmitters and activation of their receptors, possibly leading to new therapies for the treatment of dry eye syndromes.
